Mucosal Pigmentation Caused by Imatinib: Report of Three Cases

Head and Neck Pathology

Volumn 6, Issue 2, 2012, Pages 290-295

  Li, Chia Cheng ^a   Malik, Salman M ^b   Blaeser, Bart F ^c   Dehni, Walid J ^c   Kabani, Sadru P ^d   Boyle, Niamh ^e   Toner, Mary ^f   Woo, Sook Bin ^a,d,g  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b Private Practice of Orthodontia   (United States)

^c Private Practice   (United States)

^d Strata Pathology Services   (United States)

^e Private Practice   (Ireland)

^f DUBLIN DENTAL UNIVERSITY HOSPITAL   (Ireland)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chronic myeloid leukemia; Gleevec ; Imatinib mesylate; Oral mucosal pigmentation; STI 571

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; FEMALE; HARD PALATE; HUMAN; MALE; MIDDLE AGED; MOUTH MUCOSA; PATHOLOGY; PIGMENT DISORDER;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MOUTH MUCOSA; PALATE, HARD; PIGMENTATION DISORDERS; PIPERAZINES; PYRIMIDINES;

EID: 84862235593     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-011-0325-4     Document Type: Article

References (26)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl J Med. 2001; 344(14): 1031-7.
2. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med. 2002; 346(9): 645-52.
3. Savage DG, Antman KH. Imatinib mesylate-a new oral targeted therapy. New Engl J Med. 2002; 346(9): 683-93.
4. Arora B, Kumar L, Sharma A, Wadhwa J, Kochupillai V. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate. Ann Oncol. 2004; 15(2): 358-9.
5. Resende RG, Teixeira RG, Vasconcelos FD, Silva ME, Abreu MH, Gomez RS. Imatinib-associated hyperpigmentation of the palate in post-HSCT patient. J Craniomaxillofac Surg. 2011. doi: 10. 1016/j. jcms. 2011. 07. 010.
6. Lewis DM. Diffuse pigmentation of the palate. J Okla Dent Assoc. 2009; 100(8): 24-5.
7. Mattsson U, Halbritter S, Morner Serikoff E, Christerson L, Warfvinge G. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 111(5): e12-6.
8. McPherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009; 23(1): 82-3.
9. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995; 32(2 Pt 1): 241-7.
10. Granstein RD, Sober AJ. Drug- and heavy metal-induced hyperpigmentation. J Am Acad Dermatol. 1981; 5(1): 1-18.
11. Koranda FC. Antimalarials. J Am Acad Dermatol. 1981; 4(6): 650-5.
12. Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90(2): 189-94.
13. Lerman MA, Karimbux N, Guze KA, Woo SB. Pigmentation of the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107(1): 8-12.
14. Perusse R, Morency R. Oral pigmentation induced by Premarin. Cutis. 1991; 48(1): 61-4.
15. Solomon S. POMC-derived peptides and their biological action. Ann NY Acad Sci. 1999; 885: 22-40.
16. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res. 2003; 16(3): 287-96.
17. Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(6): 718-25.
18. Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol. 2002; 27(1): 8-13.
19. Issaivanan M, Mitu PS, Manisha C, Praveen K. Cutaneous manifestations of hydroxyurea therapy in childhood: case report and review. Pediatr Dermatol. 2004; 21(2): 124-7.
20. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets. 2005; 16(3-4): 181-4.
21. Hendrix JD Jr, Greer KE. Cutaneous hyperpigmentation caused by systemic drugs. Int J Dermatol. 1992; 31(7): 458-66.
22. Kelsey PR. Multiple longitudinal pigmented nail bands during hydroxyurea therapy. Clin Lab Haematol. 1992; 14(4): 337-8.
23. Meleti M, Vescovi P, Mooi WJ, van der Waal I. Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105(5): 606-16.
24. De Schepper S, Boucneau J, Lambert J, Messiaen L, Naeyaert JM. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res. 2005; 18(1): 13-24.
25. Kim IS, Kim ER, Nam HJ, Chin MO, Moon YH, Oh MR, et al. Activating mutation of GS alpha in McCune-Albright syndrome causes skin pigmentation by tyrosinase gene activation on affected melanocytes. Hormone Res. 1999; 52(5): 235-40.
26. Lin-Marq N, Borel C, Antonarakis SE. Peutz-Jeghers LKB1 mutants fail to activate GSK-3beta, preventing it from inhibiting Wnt signaling. Mol Genet Genomics. 2005; 273(2): 184-96.